Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL487778 | 0.84 | CYP11B1 (0.50) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL1549300 | 0.80 | ALDH1A1 (0.36) | ALDH1A1KDM4EMEN1KMT2ARXFP1 | |
| SCHEMBL487518 | 0.78 | CYP11B1 (0.51) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL2716190 | 0.78 | CYP11B1 (0.51) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL13859197 | 0.77 | KDM4E (0.35) | CHRNB2CHRNA4ALDH1A1KDM4EMEN1 | |
| SCHEMBL14205055 | 0.76 | CYP11B1 (0.50) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL17978217 | 0.76 | CYP11B1 (0.50) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL19835322 | 0.76 | CYP11B1 (0.50) | CYP11B1CYP11B2CHRNB2CHRNA4ALDH1A1 | |
| SCHEMBL27842672 | 0.74 | CYP11B1 (0.40) | CYP11B1CYP11B2KMT2A | |
| SCHEMBL25291420 | 0.74 | CYP11B1 (0.42) | CYP11B1CYP11B2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021026672-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2021-02-18 | — | — | WO | disclosed |